| DC5144 |
1-Azakenpaullone
Featured
|
1-Azakenpaullone is a potent and ATP-competitive GSK-3β (glycogen synthase kinase-3β) inhibitor (IC₅₀ = 18 nM). |
|
| DC11827 |
9-ING-41
Featured
|
9-ING-41 is a potent glycogen synthase kinase-3 (GSK-3) inhibitor[1]. 9-ING-41 induces apoptosis and cell cycle arrest at prophase by targeting centrosomes and microtubule-bound GSK-3β. 9-ING-41 has anticancer activity[2]. |
|
| DC11299 |
ABC 1183
Featured
|
ABC1183 is a potent, selective, orally active GSK3α/β and CDK9 inhibitor with IC50 of 327/657 nM and 321 nM (CDK9/cyclin T1), shows growth inhibitory activity against a broad panel of cancer cell lines; decreases cell survival through G2/M arrest and modu |
|
| DC8263 |
Bikinin
Featured
|
Bikinin is a strong activator of brassinosteroid (BR) signaling. |
|
| DC7663 |
BIO
Featured
|
BIO (6-bromoindirubin-3'-oxime) is a specific inhibitor of GSK-3 with IC50 of 5 nM for GSK-3α/β, shows >16-fold selectivity over CDK5, also a pan-JAKinhibitor. |
|
| DC7384 |
CHIR-98014
Featured
|
CHIR-98014 is a potent GSK-3α/β inhibitor with IC50 of 0.65 nM/0.58 nM, with the ability to distinguish GSK-3 from its closest homologs Cdc2 and ERK2. |
|
| DC9703 |
CHIR-99021 HCl
Featured
|
CHIR-99021 HCl is a potent and selective inhibitor of glycogen synthase kinase 3 beta (GSK-3β), a key enzyme involved in regulating various cellular processes, including metabolism, cell proliferation, and differentiation. By inhibiting GSK-3β, CHIR-99021 HCl modulates downstream signaling pathways, particularly the Wnt/β-catenin pathway, leading to significant biological effects both in vitro and in vivo. |
|
| DC1023 |
CHIR-99021 (CT99021)
Featured
|
CHIR-99021 is a glycogen synthase kinase 3 beta inhibitor that has antiproliferative activity in vitro and in vivo. |
|
| DC9726 |
CP21 (CP21R7)
Featured
|
CP21R7 is a potent and selective GSK-3β inhibitor. |
|
| DC4227 |
SB216763
Featured
|
SB 216763 is a potent and selective cell permeable ATP-competitive inhibitor of GSK3α with an IC50 value of 34 nM (similar potency for GSK3β). |
|
| DC2067 |
TDZD-8
Featured
|
TDZD-8 is a non-ATP competitive GSK-3β inhibitor with IC50 of 2 μM. |
|
| DC7680 |
IM-12
Featured
|
The GSK3β Inhibitor XIX, IM-12 is a selective GSK-3β inhibitor with IC50 of 53 nM, and also enhances canonical Wnt signalling. |
|
| DC1063 |
TWS119
Featured
|
TWS119 is a GSK-3β inhibitor with IC50 of 30 nM. |
|
| DC7004 |
AR-A014418(GSK3β Inhibitor VIII)
Featured
|
AR-A014418 is a selective and effective GSK3β inhibitor with an IC 50 value of 104 +/- 27 nM; no significant inhibition on 26 other kinases. |
|
| DC28275 |
BIP-135 |
BIP-135 is a potent and selective ATP-competitive GSK-3 inhibitor, with IC50s of 16 nM and 21 nM for GSK-3α and GSK-3β, respectively. BIP 135 exhibits neuroprotective effect. |
|
| DC28365 |
(Rac)-BRD0705 |
(Rac)-BRD0705 is a less active racemate of BRD0705. BRD0705 is a potent, paralog selective and orally active GSK3α inhibitor with an IC50 of 66 nM and a Kd of 4.8 μM. BRD0705 displays increased selectivity for GSK3α (8-fold) versus GSK3β (IC50 of 515 nM). BRD0705 can be used for acute myeloid leukemia (AML). |
|
| DC28691 |
GSK-3β inhibitor 2 |
GSK-3β inhibitor 2 (Compound 3) is a potent, selective and orally active GSK-3β inhibitor with an IC50 of 1.1 nM. GSK-3β inhibitor 2 can cross the blood-brain barrier. GSK-3β inhibitor 2 has the potential for Alzheimer's disease. |
|
| DC40570 |
KY19382
Featured
|
KY19382 is a potent and orally active dual inhibitor of CXXC5-DVL and GSK3β, with IC50s of 19 and 10 nM, respectively. KY19382 activates Wnt/β-catenin signaling through inhibitory effects on both CXXC5-DVL interaction and GSK3β activity. KY19382 can be us |
|
| DC41037 |
SAR502250 |
SAR502250 is a potent, selective, ATP competitive, orally active and brain-penetrant inhibitor of GSK3, with an IC50 of 12 nM for human GSK-3β. SAR502250 displays antidepressant-like activity. SAR502250 can be used for the research of Alzheimer’s disease (AD). |
|
| DC41591 |
Phospho-Glycogen Synthase Peptide-2(substrate) |
Phospho-Glycogen Synthase Peptide-2 (substrate) is peptide substrate?for glycogen synthase kinase-3 (GSK-3) and can be used for affinity purification of protein-serine kinases. |
|
| DC41592 |
Phospho-Glycogen Synthase Peptide-2(substrate) TFA |
Phospho-Glycogen Synthase Peptide-2 (substrate) is peptide substrate?for glycogen synthase kinase-3 (GSK-3) and can be used for affinity purification of protein-serine kinases. |
|
| DC41593 |
2B-(SP) |
2B-(SP) is a eIF2B-based substrate for glycogen synthase kinase-3 (GSK-3). 2B-(SP) is readily phosphorylated by both the α and β isoforms of GSK-3. |
|
| DC41594 |
2B-(SP) (TFA) |
2B-(SP) TFA is a eIF2B-based substrate for glycogen synthase kinase-3 (GSK-3). 2B-(SP) TFA is readily phosphorylated by both the α and β isoforms of GSK-3. |
|
| DC42060 |
GSK3 Substrate, α, β subunit |
GSK3 Substrate, α, β subunit is peptide substrate for glycogen synthase kinase-3 (GSK-3) and can be used to measure GSK-3 activity. |
|
| DC45693 |
Manzamine A hydrochloride |
Manzamine A hydrochloride, a member of the manzamine alkaloids, is a potent, orally active GSK-3β inhibitor (IC50=10.2 μM). Manzamine A hydrochloride shows potent activity against HSV-1 via targeting the viral gene ICP0. Manzamine A hydrochloride targets vacuolar ATPases and inhibits autophagy in pancreatic cancer cells. Manzamine A hydrochloride has antimalarial and anticancer activities. |
|
| DC45694 |
(E/Z)-GSK-3β inhibitor 1 |
(E/Z)-GSK-3β inhibitor 1 is a racemic compound of (E)-GSK-3β inhibitor 1 and (Z)-GSK-3β inhibitor 1 isomers. GSK-3β inhibitor 1 (compound 3a) is a glycogen synthase kinase 3β (GSK-3β) inhibitor and demonstrates high antidiabetic efficacy, with an IC50 of 4.9 nM. |
|
| DC46485 |
Cu(II)GTSM |
Cu(II)GTSM, a cell-permeable Cu-complex, significantly inhibits GSK3β. Cu(II)GTSM inhibits Amyloid-β oligomers (AβOs) and decreases tau phosphorylation. Cu(II)GTSM also decreases the abundance of Amyloid-β trimers. Cu(II)GTSM is a potential anticancer and antimicrobial agent. |
|
| DC48703 |
(E/Z)-BIO-acetoxime |
(E/Z)-BIO-acetoxime (GSK-3 Inhibitor X) is a potent and selective GSK-3α/β inhibitor, with an IC50 of 10 nM. (E/Z)-BIO-acetoxime shows more than 200-flod selectivity over CDK5/p25, CDK2/cyclin A and CDK1/cyclin B (IC50=2.4, 4.3, 63 μM). |
|
| DC50131 |
CHIR-98023 |
CHIR-98023 is a potent, selective and reversible inhibitor of GSK3, with IC50s of 10 nM and 6.7 nM for GSK3α and GSK3β, respectively. CHIR-98023 can improve insulin action and glucose metabolism. |
|
| DC70316 |
COB-187 |
COB-187 (COB187) is a highly potent and selective inhibitor of GSK-3 with IC50 of 22/11 nM against GSK-3α/GSK-3β.COB-187 inhibits GSK-3 phosphorylation of β-catenin and, albeit to a lesser extent, glycogen synthase.COB-187 increases the protein level of β-catenin in RAW 264.7 macrophages.COB-187 enhances β-catenin localization to the perinuclear and nuclear region in THP-1 macrophage, does not change the β-catenin mRNA level.COB-187 significantly increases the expression of the Wnt target gene cyclin D1, reduces the phosphorylation of tau in HEK293 cells transfected with tau expression vector.COB-187 inhibits only 3 kinases at >40% in a panel of 414 kinase assays, more selective relative to Tideglusib. |
|
